‌

US Patent 11382922 Aqueous oral pharmaceutical suspension compositions

Patent 11382922 was granted and assigned to ReveraGen BioPharma on July, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

ReveraGen BioPharma

0

Current Assignee

ReveraGen BioPharma

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Jesse Damsker0

John McCall0

Date of Patent

July 12, 2022

0

Patent Application Number

168119730

Date Filed

March 6, 2020

0

Patent Citations

US Patent 10464967 Non-hormonal steroid modulators of NF-κβ for treatment of disease

US Patent 10857161 Non-hormonal steroid modulators of NF-kB for treatment of disease

US Patent 10799514 Non-hormonal steroid modulators of NF-kappa beta for treatment of disease

0

US Patent 10206933 Non-hormonal steroid modulators of NF-kB for treatment of disease

0

Patent Citations Received

US Patent 11833159 Non-hormonal steroid modulators of NF-kB for treatment of disease

0

US Patent 11690853 Non-hormonal steroid modulators of NF-κβ for treatment of disease

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11382922 Aqueous oral pharmaceutical suspension compositions

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool